<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GADDUCCI, ANGIOLO</style></author><author><style face="normal" font="default" size="100%">GIULIANI, DANIELA</style></author><author><style face="normal" font="default" size="100%">COSIO, STEFANIA</style></author><author><style face="normal" font="default" size="100%">LISSONI, ANDREA</style></author><author><style face="normal" font="default" size="100%">FERRERO, ANNA MARIA</style></author><author><style face="normal" font="default" size="100%">LANDONI, FABIO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2513-2517</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.13372</style></doi><volume><style face="normal" font="default" size="100%">39</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The aim of the study was to assess the clinical outcome of patients with malignant transformation of an ovarian mature teratoma. Patients and Methods: This study was conducted on 23 patients who underwent primary surgery at three Italian Gynecological Centers. Histologically, nine (39.1%) patients had squamous cell carcinoma, five (21.7%) had a thyroid carcinoma, six (26.1%) had a carcinoid, one (4.3%) patient had papillary renal carcinoma, one (4.3%) had medulloblastoma and one (4.3%) had intestinal-type mucinous adenocarcinoma. Results: All six patients with stage I squamous cell carcinoma had no evidence of disease (NED) after a median time of 141 months. Of the three patients with stage IIb-IIIc squamous cell carcinoma, two had NED after 119 and 154 months, and one died of the disease 9 months after diagnosis. All five women with stage I thyroid carcinoma had NED after a median of 60 months. Of the six patients with stage I carcinoid, five had NED after a median of 168 months, whereas one died due to carcinoid heart disease. The three patients with stage I renal carcinoma, medulloblastoma and mucinous adenocarcinoma had NED after 24, 141 and 149 months, respectively. Conclusion: The clinical outcome of early-stage malignancies associated with mature ovarian teratomas is excellent following treatment.</style></abstract></record></records></xml>